Oncology groups that say 340B hospitals care more about money than low-income people made a revealing disclosure about their level of care for the poor during a hearing on Capitol Hill earlier this year. Dr. Debra Patt, a Texas private-practice oncologist, was testifying before the House Energy & Commerce Committee on May 17 about Medicare reimbursement. She was there on … [Read more...]
Senator Skewers Turing Pharma Exec About Disputing 340B Claims
(Reprinted from the Drug Discount Monitor) The chairwoman of the Senate Special Committee on Aging excoriated a Turing Pharmaceuticals executive during a hearing today for instructing a subordinate to dispute 340B claims in order to boost company profits. The committee was holding its second hearing about Turing's toxoplasmosis drug Daraprim and other decades-old off-patent … [Read more...]
“Pharma bro” Company’s Excuse: 340B Made Me Do It
The 340B program came up at last week's House Oversight committee hearing about drug company price gouging – the hearing during which ex-Turing Pharmaceuticals CEO Martin Shkreli pleaded the Fifth Amendment and tweeted that the committee members were imbeciles. Shkreli and Turing Chief Commercial Officer Nancy Retzlaff were there to explain why Turing raised the cost of the … [Read more...]
MedPAC Evaluates Options On Part B
May advise Congress to reduce Part B drug payments to 340B hospitalsNovember 6, 2015 -- The Medicare Payment Advisory Commission discussed options to reduce Medicare Part B drug payments to hospitals participating in the 340B program during its November public meeting, held yesterday. MedPAC previously raised this issue in its June 2015 report to Congress but made no recommendations. … [Read more...]
Americans Fed Up With High Drug Prices
The chorus has been growing for months and now it’s official: Americans across the political spectrum agree that prescription prices are too high. The drug industry could hardly have done a better job uniting the country. A new poll from the Kaiser Family Foundation finds that 72 percent of Americans believe drug costs are “unreasonable.” And in a sign of real trouble for the … [Read more...]
Cancer Drug Prices “Not Rational”
Drug companies and private cancer clinics often point fingers at safety-net hospitals in the 340B program for the rising cost of cancer care. A new study in JAMA Oncology, however, lays the blame back on industry's doorstep. With new cancer drugs now routinely costing more than $100,000 a year, researchers at the National Cancer Institute set out to learn whether such prices … [Read more...]
Infographic: 340B DSH Hospitals Have Huge Low-Income Patient Loads and Uncompensated Care Costs
Pass it along. … [Read more...]